Abbott earns FDA green light for next-gen CardioMEMS pulmonary artery pressure reader

Abbott (NYSE: ABT)+ today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.

CardioMEMS Hero features new design features to empower heart failure patients and clinicians with daily insights for detecting and combatting heart failure progression. It represents a new component of the company’s CardioMEMS HF system.

Abbott plans to begin the commercial release of the CardioMEMS Hero reader in the U.S. soon.

Sign up for Blog Updates